← Back to All Filings

Avidity (RNA) CLO Sells $1.9M in Stock for Tax Withholding

Low SignificanceDecember 19, 2025 at 8:32:37 AM EST

Avidity Biosciences, Inc.

$RNA4CIK: 0001599901

Subscribe to track RNA

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Avidity (RNA) CLO Sells $1.9M in Stock for Tax Withholding

Company: Avidity Biosciences, Inc. (RNA) Form: 4 | Filed: 2025-12-19 Significance: Low

Insider: Moriarty John B Title: Chief Legal Officer | Relationship: Officer

Transaction: • Type: Tax Withholding Sale • Shares: 26,824 • Price: $71.87 • Value: $1,928,165 • Owned After: 76,931

Key Insight: This is a non-discretionary sale to cover tax obligations from a vested stock award, not an active market sale by the insider. It carries minimal informational value.

Market Context: The sale represents approximately 0.018% of Avidity's $10.67B market capitalization, confirming its low materiality.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: Avidity Biosciences, Inc. (RNA)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Chief Legal Officer disposed of shares in a non-discretionary transaction to cover tax liabilities from a vested performance stock unit (PSU) award. This is not an open-market sale and has minimal signaling value.
  • Market Impact: Negligible. The transaction is routine and represents a tiny fraction of the company's market capitalization.

Company Information

FieldValue
CompanyAvidity Biosciences, Inc.
Ticker SymbolRNA
CIK0001599901
IndustryPHARMACEUTICAL PREPARATIONS

Insider Information

FieldValue
NameMoriarty John B
CIK0001564621
Title/PositionChief Legal Officer
RelationshipOfficer

Transaction Details

FieldValue
Form Type4
Transaction Date2025-12-17
Transaction CodeF - Payment of tax liability by withholding security
Security TypeCommon Stock
Shares Involved26,824
Price Per Share$71.87
Total Value$1,928,165.48
Shares Owned After76,931
Ownership TypeDirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$1,928,165.48
% of Market Cap0.018%
Shares Transacted26,824
% of Shares OutstandingNot Available
Post-Transaction Ownership76,931 shares
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: The transaction value of ~$1.93 million is immaterial against Avidity's market capitalization of $10.67 billion. The sale represents only 0.018% of the company's total market value, falling far below the 0.1% threshold for even moderate significance.
  • Ownership Concentration: While the number of shares outstanding is not available, the insider's post-transaction holding of 76,931 shares is noted. The sale was a partial disposition related to a larger award.
  • Transaction Significance: The filing shows two events: an award ('A') of 56,000 shares and this disposition ('F') of 26,824 shares. The 'F' code explicitly indicates a sale to cover taxes. Such transactions are automatic and do not reflect an insider's discretionary decision to sell, hence their low significance.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The market typically does not react to tax-related dispositions as they are not indicative of an insider's sentiment towards the company's future prospects.

Volume & Sentiment

  • Expected Volume Impact: None. The transaction is too small relative to the company's size to impact trading volume.
  • Sentiment Indicator: Neutral. This filing provides no bullish or bearish signal.

Additional Context

Transaction Notes

  • Special Circumstances: Footnote 2 explicitly states, "Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025." This confirms the non-discretionary nature of the sale.
Topics:#SECFiling#InsiderTrading#Form4#RNA#AvidityBiosciences#InsiderSell#StockMarket#Investing#FinancialAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.